- Osiris Therapeutics (NASDAQ:OSIR -0.5%) Q4 results: Revenues: $19.3M (+138.3%); COGS: $4.3M (+95.5%); R&D Expense: $3.9M (+105.3%); SG&A: $10M (+143.9%); Operating Income: $1.2M (+700.0%); Net Income: $1.1M (-26.7%); EPS: $0.03 (-40.0%).
- FY2014 results: Revenues: $59.9M (+146.5%); COGS: $13.2M (+97.0%); R&D Expense: $6.9M (+38.0%); SG&A: $38.1M (+145.8%); Operating Income: $1.7M (+160.7%); Net Loss: ($0.2M) (+81.8%); Loss Per Share: ($0.01) (+75.0%); Quick Assets: $39.5M (+5.7%); CF Ops: ($3.1M) (76.7%).
- No guidance given.